Glaxo paying $20M to resolve SEC charges of China bribery

/ 06:49 AM October 01, 2016

WASHINGTON  — GlaxoSmithKline PLC has agreed to pay $20 million to resolve U.S. regulators’ allegations that the pharmaceutical giant’s China operations bribed officials to boost drug sales.

The Securities and Exchange Commission announced the settlement of civil charges Friday with the British-based company, known as GSK. The company neither admitted nor denied the allegations of violating the Foreign Corrupt Practices Act, which prohibits bribery of foreign government officials or company executives to secure or retain business.


The SEC said that between 2010 and 2013, employees of GSK’s China-based subsidiary and a joint venture in the country channeled money and gifts to officials, including health care professionals. The bribes generated millions of dollars of increased drug sales to China’s state-run health institutions, the agency said.


Read Next
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Bribery, China Bribery, China operations, Drug Sales, GlaxoSmithKline PLC, Science and Health, Securities and Exchange Commission
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.